Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 1, 2016
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - July 1, 2016

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/1/16 - "Heat-Stable Dry Powder Pharmaceutical Compositions and Methods" in Patent Application Approval Process (USPTO 20160158156)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Fabio, Karine; Guarneri, Joseph J.; Curley, Kieran; Grant, Marshall L.; Leone-Bay, Andrea, filed on July 18, 2014, was made available online on June 16, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent
7/1/16 - AbbVie's HUMIRA (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis
AbbVie, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration has approved HUMIRA for the treatment of non-infectious intermediate, posterior and panuveitis. HUMIRA is now the first and only FDA- approved non-corticosteroid therapy available for adults with non infectious intermediate, posterior and.
7/1/16 - Acorda Appoints Burkhard Blank, M.D., as Chief Medical Officer (CMO)
Acorda Therapeutics, Inc. today announced that Burkhard Blank, M.D. has assumed the role of Chief Medical Officer effective immediately. I am delighted that Burkhard has joined Acorda as our CMO, said Ron Cohen, M.D., President and CEO of Acorda Therapeutics. Burkhard brings to Acorda an impressive record of successful drug development and
7/1/16 - ACORDA THERAPEUTICS INC FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits
Dr. Blank was appointed as the Company's interim CMO in January 2016, and previously served as CMO for several biopharmaceutical companies, including Boehringer Ingelheim. As CMO of Boehringer Ingelheim, Dr. Blank oversaw the submission of five New Drug Applications and had direct responsibility for all aspects of presenting at two U.S. Food and Dr
7/1/16 - Aerpio Therapeutics Reports Peer-Reviewed Publication of Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic...
By a News Reporter-Staff News Editor at Health& Medicine Week Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, announced that clinical data from the company's Phase 2 a study of its lead candidate, AKB-9778, for the treatment of patients with DME, have been published in an article
7/1/16 - Allergan Reaches Out To Family Caregivers Of People With Alzheimer's Disease With New PSA, Website
By a News Reporter-Staff News Editor at Health& Medicine Week Allergan plc, a leading global pharmaceutical company, announced its support of two new caregiver initiatives, a public service announcement and a caregiver resource website. Allergan partnered with the Alzheimer's Foundation of America and Kim Campbell wife of country music legend,
7/1/16 - Allergan Receives Positive Opinion Through European Decentralised Procedure For BELKYRA (Deoxycholic Acid) For Patients With Submental Fullness
Allergan plc, a leading global pharmaceutical company, today announced that it has received a Positive Opinion from the Swedish Medical Products Agency for BELKYRA . BELKYRA will be the first prescription medicine to be licensed in Europe for the treatment of moderate to severe convexity or fullness associated with submental fat in adults wh
7/1/16 - Allergan to Present New Data from its Anti-Infectives Portfolio at ASM Microbe 2016 in Boston
By a News Reporter-Staff News Editor at Drug Week Allergan plc, a leading global pharmaceutical company committed to the research and development of new treatments for infectious diseases, announced that new data from its anti-infectives portfolio will be featured in 14 presentations at the upcoming ASM Microbe, June 16-20, 2016, in Boston an i
7/1/16 - Alnylam Reports New Results from Investigational RNAi Therapeutic Programs for Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN) and Cardiomyopathy (hATTR-CM)
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension studies with patisiran and revusiran, both investigational RNAi therapeutics targeting transthyretin for the treatment of hereditary TTR-mediated amyloidosis. These new clinical data are being...
7/1/16 - Anthem, Express Scripts Face Legal Challenge Over Prescription Drug Prices [Seven Days (United Arab Emirates)]
Anthem and its pharmacy manager Express Scripts overcharged patients with job-based insurance for prescription drugs, alleges a lawsuit that seeks class action status for what could be tens of thousands of Americans. The case alleges that insured workers paid too much because Express Scripts charged above competitive pricing levels and Anthem, in e
7/1/16 - Arbutus Biopharma Corp. Files SEC Form 8-K, Current Report (Jun. 8, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on June 8, 2016. The SEC file number is 0000912282-16-000747.. A U.S. Securities and Exchange Commission filing is a formal d
7/1/16 - Arbutus to Present mRNA Delivery Data at the 32nd Annual Meeting of the Japan Society of Drug Delivery System
Release date- 30062016- VANCOUVER, British Columbia and DOYLESTOWN, Pa.- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced presentation of recent Lipid Nanoparticle delivery technology advancements by Dr. Peter Lutwyche, Arbutus' Chief Technology Officer, at the 32nd Annual Meeting o
7/1/16 - Array Biopharma Inc. Files SEC Form 10-Q/A, Quarterly Report [Sections 13 Or 15(D)] (Jun. 8, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on June 8, 2016. The SEC file number is 0001104659-16-126075.. A U.S. Securities and Exchange Commission filing is a formal docu
7/1/16 - Array Biopharma Inc. Files SEC Form CT ORDER, Confidential Treatment Order (Jun. 9, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on June 9, 2016. The SEC file number is 9999999997-16-023602.. A U.S. Securities and Exchange Commission filing is a formal docu
7/1/16 - Array BioPharma Pulls Back Off Best Levels But Remains Firmly Positive
WASHINGTON- After seeing initial strength, shares of Array BioPharma have given back some ground but remain firmly positive in afternoon trading on Friday. Array is currently up by 2.8 percent. The gain by Array comes after the biopharmaceutical company submitted a New Drug Application to the FDA for binimetinib in patients with advanced NRAS-mutan
7/1/16 - AstraZeneca licenses skin disease drugs to LEO Pharma
AstraZeneca has entered into an agreement with LEO Pharma for the global licence to tralokinumab in skin diseases.
7/1/16 - Aviragen Therapeutics Announces Inducement Grant for New Employee
Aviragen Therapeutics, Inc., a pharmaceutical company that is developing the next generation of antivirals, announced today that the compensation committee of the Company s Board of Directors granted to Jonas Niaura, Vice President of Business Development and Strategy, an option to purchase an aggregate of 200,000 shares of the Company s co
7/1/16 - AZ enters licensing agreements with LEO Pharma
AstraZeneca also licenses European rights to LEO Pharma for brodalumab, a potential new medicine for psoriasis. AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, Cardiovascular and Metabolic disease and Oncology.
7/1/16 - BioLineRx to Present at the JMP Securities Life Sciences Conference in New York
By a News Reporter-Staff News Editor at Drug Week BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting
7/1/16 - bioMerieux Receives FDA Clearance for Expanded Use of VIDAS B.R.A.H.M.S PCT? Test for Managing Sepsis Patients with Elevated Risk of Mortality
MARCY L ?TOILE, France Regulatory News:. bioMrieux, a world leader in the field of in vitro diagnostics, today announced that it has received 510 clearance from the U.S. Food and Drug Administration to expand the use of the VIDAS B? R? A? H? M? S PCT? assay using the change in PCT levels over time to aid in the management o
7/1/16 - BUYINS.NET Issues HedgePath Pharmaceuticals HPPI SqueezeTrigger Report
By a News Reporter-Staff News Editor at Drug Week HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced that BUYINS.NET, http://www.buyins.net/, a leading provider of Regulation SHO compliance monitoring, short sal
7/1/16 - Can-fite Biopharma Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16] (Jun. 14, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Can-fite Biopharma Ltd. was posted on June 14, 2016. The SEC file number is 0001213900-16-014189.. A U.S. Securities and Exchange Commission filing is a formal
7/1/16 - Cti Biopharma Corp. Files SEC Form CT ORDER, Confidential Treatment Order (Jun. 14, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Cti Biopharma Corp. was posted on June 14, 2016. The SEC file number is 9999999997-16-023711.. A U.S. Securities and Exchange Commission filing is a formal docu
7/1/16 - Cynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinsons Disease [Cyprus Mail]
-Cynapsus Therapeutics Inc., a specialty central nervous system pharmaceutical company developing and preparing to commercialize APL-130277, a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinsons disease, announced today that the last patient has been enrolled in its...
7/1/16 - Data from CSIR Provide New Insights into Toxicology and Pharmacology (A three-tier QSAR modeling strategy for estimating eye irritation potential of...
By a News Reporter-Staff News Editor at Drug Week Investigators publish new report on Drugs and Therapies. According to news reporting out of Uttar Pradesh, India, by NewsRx editors, research stated, "Experimental determination of the eye irritation potential of chemicals is not only tedious, time and resource intensive, it involves cruelty to te
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415